Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals

Kathleen M E Gallagher; Mark B Leick; Rebecca C Larson; Trisha R Berger; Katelin Katsis; Jennifer Y Yam; Marcela V Maus

doi:10.1093/cid/ciac201

Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals

Clin Infect Dis. 2022 Aug 24;75(1):e869-e873. doi: 10.1093/cid/ciac201.

Authors

Kathleen M E Gallagher^{1

2

3}, Mark B Leick^{2

4}, Rebecca C Larson^{2

4}, Trisha R Berger², Katelin Katsis^{1

2}, Jennifer Y Yam^{1

2}, Marcela V Maus^{2

4}

Affiliations

¹ Immune Monitoring Laboratory, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Department of Pathology, Harvard Medical School, Boston, Massachusetts, USAand.
⁴ Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Abstract

COVID-19 breakthrough cases among vaccinated individuals demonstrate the value of measuring long-term immunity to SARS-CoV-2 and its variants. We demonstrate that anti-spike T-cell responses and IgG antibody levels are maintained but decrease over time and are lower in BNT162b2- versus mRNA-1273-vaccinated individuals. T-cell responses to the variants are relatively unaffected.

Keywords: BNT162b2; SARS-CoV2 mRNA vaccine; T-cell immunity; T-cell response; mRNA-1273.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2 / genetics
T-Lymphocytes

Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding